HRP20140920T1 - Farmaceutski pripravci za lijeäśenje poremeä†aja unutrašnjeg uha - Google Patents
Farmaceutski pripravci za lijeäśenje poremeä†aja unutrašnjeg uha Download PDFInfo
- Publication number
- HRP20140920T1 HRP20140920T1 HRP20140920TT HRP20140920T HRP20140920T1 HR P20140920 T1 HRP20140920 T1 HR P20140920T1 HR P20140920T T HRP20140920T T HR P20140920TT HR P20140920 T HRP20140920 T HR P20140920T HR P20140920 T1 HRP20140920 T1 HR P20140920T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- medication
- medication according
- inner ear
- ear
- Prior art date
Links
- 208000027601 Inner ear disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 23
- 239000013543 active substance Substances 0.000 claims 5
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 4
- 210000003027 ear inner Anatomy 0.000 claims 3
- 229960003299 ketamine Drugs 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000959 ear middle Anatomy 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical group C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000017119 Labyrinth disease Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000035587 bioadhesion Effects 0.000 claims 1
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000013043 chemical agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000318 excitotoxic Toxicity 0.000 claims 1
- 230000003492 excitotoxic effect Effects 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Pripravak koji sadrži
(i) kao farmaceutski aktivno sredstvo 2-(2-klorofenil)-2-(metilamino)-cikloheksanon (ketamin), ili enantiomerni oblik ketamina, ili njegovu farmaceutski aktivnu sol, te
(ii) kao biokompatibilni polimer gel hijaluronske kiseline
naznačen time da je za uporabu kao medikament kao prevencije ili liječenja bolesti unutrašnjeg uha, pri čemu je medikament formuliran za davanje u srednje uho ili strukturu sučelja srednjeg-unutrašnjeg uha i pri čemu je farmaceutski aktivno sredstvo otopljeno ili suspendirano u gelu hijaluronske kiseline.
2. Pripravak za uporabu kao medikament prema zahtjevu 1, naznačen time da je ketamin predviđen kao hidrokloridna sol oblika njegove slobodne baze.
3. Pripravak za uporabu kao medikament prema zahtjevu 1, naznačen time da je farmaceutski aktivno sredstvo (S)-ketamin.
4. Pripravak za uporabu kao medikament prema zahtjevima 1 do 3, naznačen time da pripravak sadrži barem jedno drugo farmakološki aktivno sredstvo.
5. Pripravak za uporabu kao medikament prema bilo kojem od prethodnih zahtjeva 1 do 4 naznačen time da sadrži dodatne komponente odabrane iz skupine koju čine farmaceutski prihvatljivi nosači, puferi, pomoćne tvari, aditivi i tvari koje povećavaju permeabilnost strukture sučelja tkiva srednjeg-unutrašnjeg uha.
6. Pripravak za uporabu kao medikament prema zahtjevu 5, naznačen time da tvar koja povećava permeabilnost je histamin.
7. Pripravak za uporabu kao medikament prema bilo kojem zahtjevu od 1 do 6, naznačen time da je medikament oblikovan kao formulacija koja otpušta lijek.
8. Pripravak za uporabu kao medikament prema zahtjevu 7, naznačen time da medikament koji je formulacija koja otpušta lijek, otpušta farmaceutski aktivnu tvar tijekom nekoliko sati sve do nekoliko tjedana.
9. Pripravak za uporabu kao medikament prema bilo kojem od prethodnih zahtjeva 1 do 8, naznačen time da se medikament može injektirati i mijenja svoju viskoznost nakon umetanja u srednje uho.
10. Pripravak za uporabu kao medikament prema zahtjevima 1 do 9, naznačen time da medikament mijenja svoj profil oslobađanja izlaganjem kemijskim sredstvima.
11. Pripravak za uporabu kao medikament prema zahtjevima 1 do 10, naznačen time da je medikament za ciljano otpuštanje na odabranoj strukturi sučelja tkiva srednjeg-unutrašnjeg uha pomoću bio-adhezije ili mehaničkih svojstava.
12. Pripravak za uporabu kao medikament prema zahtjevima 1 do 11, naznačen time da je medikament predviđen u obliku implantata.
13. Pripravak za uporabu kao medikament prema bilo kojem zahtjevu od 1 do 12, naznačen time da su bolesti unutrašnjeg uha odabrane od tinitusa, gubitka sluha, upala ili infekcija unutrašnjeg uha ili, autoimunih poremećaja, vrtoglavice ili Menierove bolesti.
14. Pripravak za uporabu kao medikament prema bilo kojem zahtjevu od 1 do 13, naznačen time da su bolesti unutrašnjeg uha odabrane od ekscitotoksično izazvane degeneracije stanice uha ili degeneracije stanice uha izazvane starenjem.
15. Pripravak za uporabu kao medikament prema zahtjevu 1, naznačen time da se medikament daje putem infuzije, injekcije ili postavljanjem pomoću kirurškog instrumenta.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2005/010478 WO2007038949A1 (en) | 2005-09-28 | 2005-09-28 | Pharmaceutical compositions for the treatment of inner ear disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140920T1 true HRP20140920T1 (hr) | 2014-12-05 |
Family
ID=37019770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140920TT HRP20140920T1 (hr) | 2005-09-28 | 2014-09-25 | Farmaceutski pripravci za lijeäśenje poremeä†aja unutrašnjeg uha |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US20090246255A1 (hr) |
| EP (2) | EP2792347A1 (hr) |
| JP (1) | JP2009509982A (hr) |
| KR (1) | KR101271263B1 (hr) |
| CN (1) | CN101309667A (hr) |
| AU (1) | AU2005337107B2 (hr) |
| BR (1) | BRPI0520588B8 (hr) |
| CA (1) | CA2620374C (hr) |
| CU (1) | CU20080044A7 (hr) |
| CY (1) | CY1115891T1 (hr) |
| DK (1) | DK1928405T3 (hr) |
| EA (1) | EA017264B1 (hr) |
| ES (1) | ES2524994T3 (hr) |
| HR (1) | HRP20140920T1 (hr) |
| IL (1) | IL189622A (hr) |
| ME (1) | ME01956B (hr) |
| NO (1) | NO339356B1 (hr) |
| NZ (1) | NZ566062A (hr) |
| PL (1) | PL1928405T3 (hr) |
| PT (1) | PT1928405E (hr) |
| RS (1) | RS53591B1 (hr) |
| SI (1) | SI1928405T1 (hr) |
| TN (1) | TNSN08079A1 (hr) |
| WO (1) | WO2007038949A1 (hr) |
| ZA (1) | ZA200802762B (hr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101163481A (zh) * | 2005-03-04 | 2008-04-16 | 纽罗赛斯特克公司 | 改进的加环利定制剂 |
| PT1928405E (pt) | 2005-09-28 | 2014-10-20 | Auris Medical Ag | Composições farmacêuticas para o tratamento de distúrbios do ouvido interno |
| US20070110788A1 (en) * | 2005-11-14 | 2007-05-17 | Hissong James B | Injectable formulation capable of forming a drug-releasing device |
| WO2009006390A2 (en) | 2007-07-03 | 2009-01-08 | Charles Stark Draper Laboratory, Inc. | Drug-eluting staples prosthesis |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| CN102014957B (zh) | 2008-04-21 | 2014-12-10 | 奥德纳米有限公司 | 用于治疗耳部疾病和病况的耳用调配物 |
| MY161021A (en) | 2008-05-14 | 2017-03-31 | Otonomy Inc | Controlled release corticosteroid and methods for the treatment of otic disorders |
| US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| US8846770B2 (en) | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| WO2010011466A2 (en) | 2008-06-27 | 2010-01-28 | Otonomy, Inc. | Controlled-release cns modulating compositions and methods for the treatment of otic disorders |
| GB2461962B (en) * | 2008-07-25 | 2011-02-16 | Otonomy Inc | Slow release NMDA receptor antagonist for otic disorders |
| US8349353B2 (en) | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
| JP5491502B2 (ja) * | 2008-07-14 | 2014-05-14 | オトノミ―，インク． | 制御放出アポトーシス調節化合物および耳の障害の処置のための方法 |
| KR101367479B1 (ko) * | 2008-07-21 | 2014-03-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 귀 질병 치료를 위한 제어 방출형 항미생물성 조성물 및 방법 |
| US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| US8318817B2 (en) * | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| EP2306975A4 (en) * | 2008-07-21 | 2012-10-31 | Otonomy Inc | CONTROLLED RELEASE COMPOSITIONS MODULATING THE OTIC STRUCTURE AND MODULATING THE NATURAL IMMUNE SYSTEM AND METHODS OF TREATING OTIC DISORDERS |
| US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| CA2751761A1 (en) | 2008-10-22 | 2010-04-29 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| EP2299976A4 (en) * | 2008-12-22 | 2014-07-23 | Otonomy Inc | SELF-CONTROLLED RELEASE SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR TREATING OTIC DISORDERS |
| EP2201982A1 (en) | 2008-12-24 | 2010-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Histamine H4 receptor antagonists for the treatment of vestibular disorders |
| EP2409683A1 (en) * | 2010-07-06 | 2012-01-25 | KRKA, D.D., Novo Mesto | Stable aqueous formulations comprising poorly water soluble active ingredients |
| WO2013003669A2 (en) * | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| US10130514B2 (en) * | 2011-09-26 | 2018-11-20 | Incube Labs, Llc | System and method for delivery of a therapeutic agent to the inner ear |
| EP2790686B1 (en) | 2011-12-12 | 2021-03-10 | Zilentin Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
| US20150259277A1 (en) | 2012-10-08 | 2015-09-17 | James Wallace Sleigh | Ketamine Derivatives |
| US20140348787A1 (en) * | 2013-05-22 | 2014-11-27 | Professional Compounding Centers Of America | Methods and Compositions for Treating Ear Infections |
| WO2015031393A1 (en) | 2013-08-27 | 2015-03-05 | Otonomy, Inc. | Treatment of pediatric otic disorders |
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| WO2015051259A1 (en) * | 2013-10-04 | 2015-04-09 | Impax Laboratories, Inc. | Pharmaceutical compositions and methods of use |
| WO2015191950A1 (en) * | 2014-06-12 | 2015-12-17 | Orbis Biosciences, Inc. | Extended-release drug delivery compositions |
| WO2017139382A1 (en) * | 2016-02-08 | 2017-08-17 | The Texas A&M University System | Combination of adjuvant drugs esketamine and brimonidine for medical treatments |
| WO2018053173A1 (en) | 2016-09-16 | 2018-03-22 | Otonomy, Inc. | Otic gel formulations for treating otitis externa |
| KR20230110828A (ko) * | 2018-01-10 | 2023-07-25 | 엑스더블유파마 리미티드 | 케타민의 전구약물, 및 이의 조성물 및 용도 |
| AU2019218232A1 (en) | 2018-02-09 | 2020-09-24 | Decibel Therapeutics, Inc. | Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent |
| CN111936127A (zh) | 2018-02-15 | 2020-11-13 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| WO2019186357A1 (en) * | 2018-03-26 | 2019-10-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CN118121577A (zh) | 2018-05-04 | 2024-06-04 | 感知神经科学公司 | 治疗物质滥用的方法 |
| US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
| US20200214976A1 (en) * | 2019-01-09 | 2020-07-09 | Spiral Therapeutics, Inc. | Self-gelling solutions for administration of therapeutics to the inner ear |
| JP2023538901A (ja) * | 2020-08-18 | 2023-09-12 | オークウッド ラボラトリーズ，エル．エル．シー． | ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法 |
| WO2022140636A1 (en) * | 2020-12-22 | 2022-06-30 | Otonomy, Inc. | Gacyclidine otic formulations and uses thereof |
| US11753378B2 (en) | 2021-04-19 | 2023-09-12 | Zevra Therapeutics, Inc. | Ketamine compounds and processes for making and using them |
| US11690811B2 (en) | 2021-08-13 | 2023-07-04 | XWPharma Ltd. | Pharmaceutical compositions and oral dosage forms of ketamine derivatives |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3254124A (en) * | 1962-06-29 | 1966-05-31 | Parke Davis & Co | Aminoketones and methods for their production |
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| US5421818A (en) * | 1993-10-18 | 1995-06-06 | Inner Ear Medical Delivery Systems, Inc. | Multi-functional inner ear treatment and diagnostic system |
| EP0772225B1 (en) * | 1994-07-15 | 2003-03-19 | Hitachi, Ltd. | Electronic energy filter |
| DE69434794T2 (de) * | 1994-09-22 | 2007-07-12 | Smith, Richard Alan, La Jolla | Kombination von dextromethorphan mit quinidine oder quinine sulfat zur behandlung verschiedener refraktärer störungen |
| US5945409A (en) * | 1995-03-10 | 1999-08-31 | Wilson T. Crandall | Topical moisturizing composition and method |
| US5654337A (en) * | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
| DE19528388A1 (de) | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
| TW450807B (en) * | 1995-09-15 | 2001-08-21 | Pfizer | Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents |
| AU2676397A (en) | 1996-04-18 | 1997-11-07 | University Technology Corporation | Methods for treating middle and inner ear disorders |
| WO1998010757A2 (en) | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity |
| US6045528A (en) | 1997-06-13 | 2000-04-04 | Intraear, Inc. | Inner ear fluid transfer and diagnostic system |
| US6309410B1 (en) | 1998-08-26 | 2001-10-30 | Advanced Bionics Corporation | Cochlear electrode with drug delivery channel and method of making same |
| DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
| US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
| KR20070058028A (ko) * | 1999-05-24 | 2007-06-07 | 소너스파머슈티칼즈인코포레이티드 | 난용성 약물용 에멀젼 부형제 |
| US6017961A (en) | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
| DE19936719A1 (de) * | 1999-08-06 | 2001-02-15 | Gruenenthal Gmbh | Substituierte 1,5-Dihydropyrrol-2-on-Derivate |
| US6265379B1 (en) * | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
| JP2001187737A (ja) * | 1999-10-18 | 2001-07-10 | Toyama Chem Co Ltd | 聴力改善剤 |
| AU2001257295A1 (en) | 2000-05-01 | 2001-11-12 | Georgetown University | In vivo assay for identifying nucleic acid sequences involved in alveolar loss, development and nucleic acid sequences identified thereby |
| DE10025238A1 (de) * | 2000-05-22 | 2001-11-29 | Gruenenthal Gmbh | Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel |
| BRPI0002693B8 (pt) | 2000-06-19 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis |
| DE10044649A1 (de) * | 2000-09-08 | 2002-07-04 | Gruenenthal Gmbh | Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine |
| US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
| DE10124953A1 (de) | 2001-05-21 | 2002-12-12 | Marlies Knipper | Substanz für die therapeutische Behandlung von Tinnitus |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| US20030143195A1 (en) * | 2002-01-30 | 2003-07-31 | Pinsker Judy Senior | Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
| US6638081B2 (en) * | 2002-03-22 | 2003-10-28 | Hon Hai Precision Ind. Co., Ltd. | Electrical connector |
| US20040037311A1 (en) | 2002-08-07 | 2004-02-26 | Phonex Broadband Corporation | Digital narrow band power line communication system |
| JP2006502158A (ja) * | 2002-09-06 | 2006-01-19 | デュレクト コーポレーション | グルタメート媒介神経伝達のモジュレーターの内耳への送達 |
| US6969383B2 (en) * | 2002-09-27 | 2005-11-29 | Medtronic, Inc. | Method for treating severe tinnitus |
| US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
| DE50312412D1 (en) * | 2002-11-12 | 2010-03-25 | Gruenenthal Gmbh | 4-hydroxymethyl-1-aryl-cyclohexylamin-derivative |
| US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
| EP1438942A1 (en) | 2003-01-17 | 2004-07-21 | Schering Oy | An otorhinological drug delivery device |
| ATE446791T1 (de) | 2003-05-16 | 2009-11-15 | Univ Laval | Cns chlorid-modulierung und verwendung derselben |
| EP1699431B1 (en) | 2003-12-12 | 2015-08-19 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| US8268866B2 (en) * | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| PT1928405E (pt) | 2005-09-28 | 2014-10-20 | Auris Medical Ag | Composições farmacêuticas para o tratamento de distúrbios do ouvido interno |
-
2005
- 2005-09-28 PT PT05797324T patent/PT1928405E/pt unknown
- 2005-09-28 US US11/992,632 patent/US20090246255A1/en not_active Abandoned
- 2005-09-28 PL PL05797324T patent/PL1928405T3/pl unknown
- 2005-09-28 CN CNA2005800517036A patent/CN101309667A/zh active Pending
- 2005-09-28 JP JP2008532601A patent/JP2009509982A/ja active Pending
- 2005-09-28 EA EA200800798A patent/EA017264B1/ru not_active IP Right Cessation
- 2005-09-28 EP EP14001796.3A patent/EP2792347A1/en not_active Withdrawn
- 2005-09-28 ME MEP-2014-138A patent/ME01956B/me unknown
- 2005-09-28 DK DK05797324T patent/DK1928405T3/da active
- 2005-09-28 NZ NZ566062A patent/NZ566062A/en not_active IP Right Cessation
- 2005-09-28 EP EP05797324.0A patent/EP1928405B1/en active Active
- 2005-09-28 KR KR1020087007345A patent/KR101271263B1/ko active IP Right Grant
- 2005-09-28 CA CA 2620374 patent/CA2620374C/en active Active
- 2005-09-28 WO PCT/EP2005/010478 patent/WO2007038949A1/en active Application Filing
- 2005-09-28 RS RSP20140607 patent/RS53591B1/en unknown
- 2005-09-28 ES ES05797324.0T patent/ES2524994T3/es active Active
- 2005-09-28 CU CU20080044A patent/CU20080044A7/es unknown
- 2005-09-28 AU AU2005337107A patent/AU2005337107B2/en not_active Ceased
- 2005-09-28 SI SI200531901T patent/SI1928405T1/sl unknown
- 2005-09-28 BR BRPI0520588A patent/BRPI0520588B8/pt active IP Right Grant
-
2008
- 2008-02-20 IL IL189622A patent/IL189622A/en active IP Right Grant
- 2008-02-21 TN TNP2008000079A patent/TNSN08079A1/en unknown
- 2008-03-28 ZA ZA2008/02762A patent/ZA200802762B/en unknown
- 2008-04-22 NO NO20081919A patent/NO339356B1/no not_active IP Right Cessation
-
2014
- 2014-06-27 US US14/317,319 patent/US9066865B2/en active Active
- 2014-09-25 HR HRP20140920TT patent/HRP20140920T1/hr unknown
- 2014-12-02 CY CY20141101004T patent/CY1115891T1/el unknown
-
2015
- 2015-03-27 US US14/671,527 patent/US20150265532A1/en not_active Abandoned
- 2015-03-27 US US14/671,524 patent/US20150196569A1/en not_active Abandoned
- 2015-05-22 US US14/720,212 patent/US20150250719A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140920T1 (hr) | Farmaceutski pripravci za lijeäśenje poremeä†aja unutrašnjeg uha | |
| RU2334525C2 (ru) | Оторинологическое доставляющее устройство | |
| Schopf et al. | Topical ocular drug delivery to the back of the eye by mucus-penetrating particles | |
| BRPI0513243B8 (pt) | composições oftálmicas e respectivos usos | |
| AR058620A1 (es) | Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo | |
| DK1487829T3 (da) | Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte | |
| AR048646A1 (es) | Implante intraocular o intravitreo biodegradable que comprende un inhibidor de tirosina quinasa y un polimero biodegradable, metodo para producirlo y medicamento correspondiente | |
| BRPI0517891A (pt) | composições compreendendo azelastina e métodos de uso das mesmas | |
| AR045039A1 (es) | Dispositivo de administracion de drogas oftalmicas | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| JP2013535485A (ja) | 薬物の持続送達のためのコラーゲン系インプラント | |
| CN106344495A (zh) | 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物 | |
| JP2012506436A (ja) | 代謝型グルタミン酸受容体の調節による内耳の疾病の処置および／または予防 | |
| DE602004009552D1 (de) | Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel | |
| JP2018533629A5 (hr) | ||
| EA201170004A1 (ru) | Использование антагонистов h4-гистаминовых рецепторов для лечения послеоперационных спаек | |
| KR101412776B1 (ko) | 각결막염 치료용 점안제 조성물 및 이의 제조 방법 | |
| JP2008189677A (ja) | 洗浄剤 | |
| JP2003146892A (ja) | 洗浄剤 | |
| ES2581247T3 (es) | Agente terapéutico para la enfermedad corneal | |
| US10245274B2 (en) | Chitosan-based matrices and uses thereof | |
| ATE477021T1 (de) | 1,3,5-triazepin-dionen zur behandlung von malaria | |
| DE20321445U1 (de) | Otorhinologische Abgabevorrichtung | |
| KR20170102892A (ko) | 테트라카인계 마취제 | |
| UA119260C2 (uk) | Ін'єкційна гелеподібна водна композиція для проведення місцевої анестезії |